PNC-27
PNC27 · p53 12-26-MRP
A p53-derived peptide (residues 12–26 fused to a membrane-residency sequence) that kills some cancer cell lines in vitro by binding membrane HDM-2 and forming pores (PMID 20080680). It is not FDA-approved, not a cancer treatment, and has no Phase 3 program. Gray-market vials exist anyway - this leaf is identity, mechanism, and reconstitution math plus a hard “do not self-treat cancer” line.
Quick answer
What it is: A p53-derived peptide (residues 12–26 fused to a membrane-residency sequence) that kills some cancer cell lines in vitro by binding membrane HDM-2 and forming pores (PMID 20080680).
Typical research dose: No established human dose - preclinical / cell-line research only
Research summary, not medical advice.
Use-case scores
- Immune1.5/10
Compound card
- Class
- p53-derived anticancer research peptide
- Formula
- p53 12–26 + MRP
- Status
- Not FDA-approved · research use
How it works
PNC-27 is p53 residues 12–26 fused to a membrane-residency peptide. In cell lines it binds membrane HDM-2 on some transformed cells and forms pores, causing necrosis independent of nuclear p53 (PMID 20080680). Mouse xenograft work exists. There is no approved indication, no Phase 3, and no established human dose.
Gray-market vials are not a cancer protocol. This page is identity, citation, and reconstitution arithmetic - plus a refusal to dress it up as treatment.
Source: PMID: 20080680 (PNAS 2010); PMID: 25117093
Not a cancer treatment
PNC-27 is preclinical. Buying a research vial is not oncology. Do not delay standard care. We will not print a “cycle” as if this were BPC-157.
Research Use Cases
- ✓Oncology research identity: Low
Dosing
| Phase | Dose | Frequency | Notes |
|---|---|---|---|
| Human | None established | n/a | Calculator defaults are vial math only. They are not a protocol. |
Administration
Timeline
Who it is for
Oncology research identity
LowLegitimate papers, illegitimate consumer use. Listed so the library is honest about what the SKU is.
Reconstitution
| Vial | Water | Concentration | Example dose |
|---|---|---|---|
| 5 mg lyophilized | 2 mL BAC | 2.5 mg/mL | Identity only. Not a home oncology protocol. |
Change vial size or water volume? Open the reconstitution calculator.
Safety & Considerations
No human safety database sufficient for self-administration. Pore-forming peptides are not “gentle recovery compounds.” Not FDA-approved. Not a substitute for oncology care.
Regulatory & Legal Status
Preclinical oncology peptide. Not a cancer treatment. No FDA approval or Phase 3 program
Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Limits of current evidence
- Not an oncology NDA.
- Do not sell this as an alternative to indicated cancer care.
Verdict
PNC-27 is a p53-derived research peptide from cancer-cell papers. This site will not treat cancer. Gray-market “cancer peptides” are a harm pattern.
Interactions & Contraindications
No human safety database sufficient for self-administration. Pore-forming peptides are not “gentle recovery compounds.” Not FDA-approved. Not a substitute for oncology care.
Frequently Asked Questions
Is PNC-27 FDA-approved for cancer?▼
Why is it in a reconstitution library?▼
References
- Sarafraz-Yazdi E et al. “PNC-27 binds membrane HDM-2 and kills cancer cells.” PNAS (2010). PMID: 20080680
- Davitt K et al. “PNC-27 in a p53-null leukemia line.” Ann Clin Lab Sci (2014). PMID: 25117093
Prescription options: compare licensed telehealth providers
Some peptide therapies are available only by prescription after a consult with a licensed clinician.